EUVIMEDEUVIMED entdecken
Crossref

Triazolo[1,5‐a]Pyrimidine Derivatives as Selective EGFR Inhibitors: Synthesis, Cytotoxicity, Molecular Docking, and DFT Studies

Swetha Madamala, S. Chandrasekhar, Abdulrahman G. Alhamzani, Mortaga M. Abou‐Krisha, Ehab A. Abdelrahman, K. Yogesh Kumar, M. S. Raghu, M. K. Prashanth

ChemistrySelect · 2026-07 · 11 (27)

DOI: 10.1002/slct.73836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 14.07.2026. Verfasst von Swetha Madamala und 7 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of triazolo[1,5‐a]pyrimidine derivatives ( 6a–c ) were synthesized and evaluated as potential epidermal growth factor receptor (EGFR) inhibitors. The synthesized compounds were characterized by elemental analysis and spectroscopic techniques. Utilizing the MTT assay and erlotinib as a reference, the cytotoxic potential of the compounds was assessed against the MCF‐7 and MDA‐MB‐231 cancer cell lines. Compound 6c showed the greatest potency (IC 50 = 2.19 µM for MCF‐7 and 4.55 µM for MDA‐MB‐231), while showing low toxicity toward normal WI‐38 cells. Potent activity was demonstrated by in vitro EGFR tyrosine kinase inhibition tests, where compound 6c (IC 50 = 0.85 µM) outperformed erlotinib. The docking study against EGFR tyrosine kinase showed effective binding of 6c with docking score −10.26 kcal/mol having hydrogen‐bond interaction with Cys‐797, Tyr‐ 801, and Tyr‐ 891 along with π–π stacking interactions with Trp‐817. DFT simulations indicated that compound 6c possessed the largest HOMO–LUMO energy gap (4.3887 eV), chemical hardness (2.1943 eV), and electrophilicity index (6.2626 eV), suggesting enhanced electronic stability and reactivity. ADMET predictions revealed favorable drug‐likeness characteristics with LogP value of 2.68, TPSA of 43.08 Å 2 , and no violations of Lipinski's and Veber's rules. Overall, compound 6c emerged as a promising lead candidate for the development of selective EGFR‐targeted anticancer agents.

Zitieren

APA

Madamala, S., Chandrasekhar, S., Alhamzani, A. G., Abou‐Krisha, M. M., Abdelrahman, E. A., Kumar, K. Y., Raghu, M. S., & Prashanth, M. K. (2026). Triazolo[1,5‐a]Pyrimidine Derivatives as Selective EGFR Inhibitors: Synthesis, Cytotoxicity, Molecular Docking, and DFT Studies. ChemistrySelect, 11(27). https://doi.org/10.1002/slct.73836

Vancouver

Madamala S, Chandrasekhar S, Alhamzani AG, Abou‐Krisha MM, Abdelrahman EA, Kumar KY, et al. Triazolo[1,5‐a]Pyrimidine Derivatives as Selective EGFR Inhibitors: Synthesis, Cytotoxicity, Molecular Docking, and DFT Studies. ChemistrySelect. 2026;11(27). doi:10.1002/slct.73836

BibTeX
@article{Madamala2026,
  author = {Madamala, Swetha and Chandrasekhar, S. and Alhamzani, Abdulrahman G. and Abou‐Krisha, Mortaga M. and Abdelrahman, Ehab A. and Kumar, K. Yogesh and Raghu, M. S. and Prashanth, M. K.},
  title = {Triazolo[1,5‐a]Pyrimidine Derivatives as Selective EGFR Inhibitors: Synthesis, Cytotoxicity, Molecular Docking, and DFT Studies},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {27},
  doi = {10.1002/slct.73836}
}
Kostenlos starten →